# Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Coronary Artery Disease

> **NCT00312052** · PHASE2 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 720 (actual)

## Conditions studied

- Coronary Artery Disease

## Interventions

- **DRUG:** E5555
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00312052
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2008-03
- **Final completion:** 2009-08
- **Target enrollment:** 720 (ACTUAL)
- **Last updated:** 2016-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00312052

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00312052, "Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Coronary Artery Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00312052. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*